Arce Joan-Carles, Smitz Johan
Reproductive Health, Global Clinical & Non-Clinical R&D, Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
Hum Fertil (Camb). 2011 Sep;14(3):192-9. doi: 10.3109/14647273.2011.587135. Epub 2011 Jul 7.
To evaluate, retrospectively, the roles of endogenous and exogenous luteinising hormone (LH) activity on live birth rate in ovulation induction cycles.
Associations between LH activity at baseline, end of stimulation and live birth rate were analysed in relation to patient characteristics, baseline and end of stimulation variables in WHO group II anovulatory women (n = 155) stimulated with recombinant follicle-stimulating hormone (rFSH) or highly purified human menopausal gonadotrophin (HP-hMG). HP-hMG provides FSH and exogenous LH activity mainly in the form of human chorionic gonadotrophin (hCG).
Serum LH concentrations at baseline or end of stimulation were not predictive of live birth rate in the rFSH group (n = 79) or HP-hMG group (n = 76). Serum hCG concentration at end of stimulation was a significant positive predictor in HP-hMG-treated women. Other variables were not independently predictive of live birth in either of the groups, except for a negative association between serum FSH concentrations at the start of stimulation and live birth in the rFSH-treated group.
Endogenous LH concentrations are not predictive of live birth in anovulatory WHO group II patients undergoing ovulation induction with rFSH or HP-hMG. On the other hand, exogenous hCG activity during HP-hMG stimulation is positively associated with treatment outcome.
回顾性评估内源性和外源性促黄体生成素（LH）活性在排卵诱导周期中对活产率的作用。
分析了世界卫生组织II型无排卵女性（n = 155）在接受重组促卵泡激素（rFSH）或高度纯化的人绝经期促性腺激素（HP-hMG）刺激时，基线、刺激结束时的LH活性与活产率之间的关联，并结合患者特征、基线和刺激结束时的变量进行分析。HP-hMG主要以人绒毛膜促性腺激素（hCG）的形式提供促卵泡激素和外源性LH活性。
在rFSH组（n = 79）或HP-hMG组（n = 76）中，基线或刺激结束时的血清LH浓度均不能预测活产率。刺激结束时的血清hCG浓度是HP-hMG治疗女性活产率的显著正性预测指标。除了rFSH治疗组刺激开始时血清促卵泡激素浓度与活产率呈负相关外，其他变量在两组中均不能独立预测活产率。
对于接受rFSH或HP-hMG诱导排卵的世界卫生组织II型无排卵患者，内源性LH浓度不能预测活产率。另一方面，HP-hMG刺激期间的外源性hCG活性与治疗结局呈正相关。
